Latest Regulatory Milestones News

Clarity Pharmaceuticals reports a robust cash position and strategic refocus on its lead prostate cancer asset, Cu-SAR-bisPSMA, supported by multiple FDA Fast Track designations and advancing clinical trials.

Bindi Metals progresses its Lisa Project application with Serbia’s Ministry while identifying promising gold and antimony drill targets, maintaining a solid cash position of $1.734 million.

Enova Mining reports significant high-grade titanium discoveries at its CODA North and Central projects in Brazil, supported by a $1.5 million placement to accelerate exploration and development.

Dimerix Limited advances its Phase 3 kidney disease trial with FDA acceptance of proteinuria as a primary endpoint and clinches a lucrative licensing agreement in Japan worth up to AU$107 million plus royalties.

TrivarX has launched a pivotal mental health clinical trial in partnership with the US Department of Veterans Affairs, leveraging its innovative ECG-based technology to screen for major depressive episodes. The company also secured $2.25 million in funding, positioning it for regulatory milestones ahead.

Hydrix Limited reports improved operating performance in Q3 FY25, buoyed by FDA clearance of its Gyder Surgical Hip Navigation system and a reduced cash operating loss, while managing tight liquidity with shareholder support.

Blue Energy has resolved a significant legal hurdle by securing an amended Environmental Authority for its Sapphire asset, enabling progression of the Petroleum Lease 1034 and continued pilot production testing despite operational interruptions.

Arizona Lithium advances its Prairie Project with a pioneering commercial development plan for lithium brine extraction, regulatory approvals, and a $1.3 million capital raise to fund initial production.

Alligator Energy Limited has made significant strides in its uranium exploration and development projects, securing critical regulatory approvals and advancing field operations while maintaining a robust cash position. The company’s strategic investments and ongoing drilling programs position it well amid a strengthening uranium market.

Alterity Therapeutics reports compelling Phase 2 clinical trial results for ATH434 in Multiple System Atrophy, alongside a significant capital raise strengthening its financial position for upcoming regulatory milestones.

Genesis Resources has completed its acquisition of full ownership of the Plavica JV in North Macedonia and is progressing environmental studies and exploration planning for multiple Australian tenements ahead of 2025 drilling campaigns.

Vanadium Resources Limited has extended its EPC and financing MOU with China Energy and raised A$783,000 via convertible notes, supporting ongoing development of its Steelpoortdrift Vanadium Project amid cost controls and regulatory progress.